Azacitidine
Azacitidine is an active ingredient of the class «antimetabolite».
Chemical compound
What it is used for
- Chronic myelomonocytic leukemia
- Myelofibrosis
- Acute myeloid leukemia
- Refractory anemia with excess blasts in transformation
- Myelodysplastic syndrome
- Refractory anemia with excess of blasts
- Neoplasm
ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.
Vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with: intermediate 2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS), chronic…
How it works
- DNA (cytosine-5)-methyltransferase 3A inhibitor
- DNA (cytosine-5)-methyltransferase 1 inhibitor
- DNA inhibitor
- RNA inhibitor
Class: antimetabolite
Common side effects
The following clinically significant adverse reactions are described elsewhere in the labeling: • Myelosuppression The most common adverse reactions (≥ 10%) are nausea, vomiting, diarrhea, fatigue/asthenia, constipation, upper respiratory tract infection, pneumonia, abdominal pain, arthralgia, decreased appetite…
Who should not take it
ONUREG is contraindicated in patients with known severe hypersensitivity to azacitidine or its components. History of severe hypersensitivity to azacitidine or its components.
Pregnancy and breastfeeding
Based on its mechanism of action and findings in animals, ONUREG can cause fetal harm when administered to a pregnant woman. There are no available data on ONUREG use in pregnant women to evaluate for a drug-associated risk.
Brand names
United States
Onureg · Vidaza
European Union
Azacitidine Accord · Azacitidine betapharm · Azacitidine Kabi · Azacitidine Mylan · Onureg · Vidaza
Canada
Onureg · Vidaza
Other trade names
Azacitidine celgene
Approval status
- US Food and Drug Administration
- prescription · since 2004
- European Medicines Agency
- authorised · since 2008
- Health Canada
- prescription · marketed
- First approval anywhere
- 2004
Codes
- ATC
- L01BC07
- RxNorm CUI
- 1251
- ChEMBL
- CHEMBL1489
- PubChem CID
- 9444
- UNII
- M801H13NRU
- Wikidata
- Q416451
Frequently asked questions
What is Azacitidine used for?
Azacitidine is used for: Chronic myelomonocytic leukemia, Myelofibrosis, Acute myeloid leukemia, Refractory anemia with excess blasts in transformation, Myelodysplastic syndrome, Refractory anemia with excess of blasts, and Neoplasm.
What kind of medicine is Azacitidine?
Azacitidine is an active ingredient of the class «antimetabolite».
What are the brand names of Azacitidine?
Brand names of Azacitidine include Onureg, Vidaza, Azacitidine Accord, Azacitidine betapharm, Azacitidine Kabi, Azacitidine Mylan, and Azacitidine celgene.
Medicines in the same class
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)